Enliven Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $85.9M | $80.8M | $64.6M | $31.0M | $38.4M |
| Operating expenses | $119.7M | $104.6M | $83.5M | $38.8M | $51.4M |
| Operating income | -$119.7M | -$104.6M | -$83.5M | -$38.8M | -$51.4M |
| Pretax income | — | — | — | $1.6M | -$51.4M |
| Income tax expense | $0 | $232,000 | $0 | $0 | — |
| Net income | -$103.7M | -$89.0M | -$71.6M | -$37.7M | -$51.4M |
| Balance Sheet | |||||
| Cash and equivalents | $98.9M | $124.1M | $100.1M | $75.5M | $48.3M |
| Current assets | $474.9M | $318.1M | $266.2M | $77.8M | $92.7M |
| Total assets | $476.2M | $325.8M | $271.9M | $83.3M | $93.6M |
| Current liabilities | $16.6M | $15.9M | $25.9M | $9.7M | $7.2M |
| Total liabilities | $16.6M | $15.9M | $26.0M | $10.4M | $7.6M |
| Stockholders' equity | $459.6M | $309.8M | $245.9M | -$76.8M | -$42.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$70.3M | -$73.2M | -$61.3M | -$32.1M | -$46.8M |
| Depreciation and amortization | $300,000 | $300,000 | $300,000 | $200,000 | $99,000 |
| Stock-based compensation | $34.0M | $20.2M | $12.9M | $3.2M | $3.8M |
| Capital expenditure | $158,000 | $44,000 | $149,000 | $612,000 | $12,000 |
| Free cash flow | -$70.5M | -$73.2M | -$61.4M | -$32.7M | -$46.8M |
| Impairments | $0 | $0 | — | — | — |
Shares outstanding 60.9M · Free float 54.5%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.